tbuckley/cabot-search huggingface dataset:
P77.04 PROPEL: A Phase 1/2 Trial of Bempegaldesleukin (NKTR-214) Plus Pembrolizumab in Lung Cancer and other Advanced Solid Tumors
Authors: D.R. Spigel, D. Rodríguez-Abreu, F. Cappuzzo, V. Velcheti, A.K. Ganti, D. Johnson, R. Govindan, S. Antonia, B. Besse, M. Altan, M. Edelman, S. Ramalingam, E. Felip, S. Gadgeel, O. Juan-Vidal, A. Gupta, S. Currie, W. Lin, M. Tagliaferri, M. Reck
Journal: Journal of Thoracic Oncology (2021)
Regorafenib enhances antitumor immunity via inhibition of p38 kinase/Creb1/Klf4 axis in tumor-associated macrophages
Authors: Da-Liang Ou, Chia-Wei Chen, Chia-Lang Hsu, Chih-Hung Chung, Zi-Rui Feng, Bin-Shyun Lee, Ann-Lii Cheng, Muh-Hwa Yang, Chiun Hsu
Journal: Journal for ImmunoTherapy of Cancer (2021)

Regorafenib and other multikinase inhibitors may enhance antitumor efficacy of anti-program cell death-1 (anti-PD1) therapy in hepatocellular carcinoma (HCC). Its immunomodulatory effects, besides anti-angiogenesis, were not clearly defined.
Combination of long-acting TRAIL and tumor cell-targeted photodynamic therapy as a novel strategy to overcome chemotherapeutic multidrug resistance and TRAIL resistance of colorectal cancer
Authors: Tianshan She, Qiuxiao Shi, Zhao Li, Yanru Feng, Hao Yang, Ze Tao, Heng Li, Jie Chen, Shisheng Wang, Yan Liang, Jingqiu Cheng, Xiaofeng Lu
Journal: Theranostics (2021)

Chemotherapeutic multidrug resistance (MDR) is the major hindrance for clinical therapy of colorectal cancer (CRC). Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) with selective cytotoxicity might overcome MDR of CRC cells. Unfortunately, cross-resistance to TRAIL has been detected in many CRC cells, suggesting the need to combine TRAIL with sensitizers to combat refractory CRC. Our purpose is to explore the potential of combination therapy of TRAIL and tumor-cell targeted photodynamic therapy (PDT) in combating CRC with both chemotherapeutic MDR and TRAIL resistance. Methods: Tumor cell-targeted PDT was performed using a Ze-IR700 photosensitizer with high affinity for epidermal growth factor receptor (EGFR). The impact of PDT on the gene expression of CRC cells was revealed by RNA sequencing. The synergistic antitumor effect of long-acting TRAIL and PDT was evaluated in mice bearing tumor grafts of CRC cells with both chemotherapeutic MDR and TRAIL resistance. Results: Chemotherapeutic MDR and TRAIL resistance are common in CRC cells. Pretreatment of CRC cells with tumor cell-targeted PDT significantly (10-60 times) increased the sensitivity of these CRC cells to TRAIL by upregulating death receptors. Combination therapy, but not monotherapy, of long-acting TRAIL and PDT greatly induced apoptosis of CRC cells, thus efficiently eradicated large (~150 mm3) CRC tumor xenografts in mice. Conclusions: Tumor cell-targeted PDT extensively sensitizes CRC cells to TRAIL. Combination therapy of long-acting TRAIL and PDT is promising to combat CRC with both chemotherapeutic MDR and TRAIL resistance, which might be developed as a novel strategy for precision therapy of refractory CRC.
BIO21-011: Oncology Provider Perspectives on Telemedicine for Patients With Cancer: A National Comprehensive Cancer Network (NCCN®) Survey
Authors: Amye Tevaarwerk, Travis Osterman, Waddah Arafat, Jeffrey Smerage, Fernanda C.G. Polubriaginof, Tricia Heinrichs, Jessica Sugalski, Daniel Martin
Journal: Journal of the National Comprehensive Cancer Network (2021)

"BIO21-011: Oncology Provider Perspectives on Telemedicine for Patients With Cancer: A National Comprehensive Cancer Network (NCCN®) Survey" published on 17 Mar 2021 by National Comprehensive Cancer Network.
County-Level COVID-19 Vaccination Coverage and Social Vulnerability — United States, December 14, 2020–March 1, 2021
Authors: Michelle M. Hughes, Alice Wang, Marissa K. Grossman, Eugene Pun, Ari Whiteman, Li Deng, Elaine Hallisey, J. Danielle Sharpe, Emily N. Ussery, Shannon Stokley, Trieste Musial, Daniel L. Weller, Bhavini Patel Murthy, Laura Reynolds, Lynn Gibbs-Scharf, LaTreace Harris, Matt D. Ritchey, Robin L. Toblin
Journal: MMWR Morbidity and Mortality Weekly Report (2021)

This report describes how national COVID-19 vaccination coverage was lower in counties with some of the most socially vulnerable communities and higher in counties with some of the least socially vulnerable communities.
P47.10 Predicting ROR1/BCL2 Combination Targeted Therapy of Small Cell Carcinoma of the Lung
Authors: W. Wang, K. Shilo, J. Amann, A. Shulman, M. Hojjat-Farsangi, H. Mellstedt, J. Schultz, C. Croce, D. Carbone
Journal: Journal of Thoracic Oncology (2021)
P03.02 Neoadjuvant Osimertinib with/without Chemotherapy vs Chemotherapy for EGFR Mutated Resectable NSCLC: NeoADAURA
Authors: M. Tsuboi, W. Weder, C. Escriu, C. Blakely, J. He, S. Dacic, Y. Yatabe, L. Zeng, A. Walding, J. Chaft
Journal: Journal of Thoracic Oncology (2021)
Infection- and vaccine-induced antibody binding and neutralization of the B.1.351 SARS-CoV-2 variant
Authors: Venkata Viswanadh Edara, Carson Norwood, Katharine Floyd, Lilin Lai, Meredith E. Davis-Gardner, William H. Hudson, Grace Mantus, Lindsay E. Nyhoff, Max W. Adelman, Rebecca Fineman, Shivan Patel, Rebecca Byram, Dumingu Nipuni Gomes, Garett Michael, Hayatu Abdullahi, Nour Beydoun, Bernadine Panganiban, Nina McNair, Kieffer Hellmeister, Jamila Pitts, Joy Winters, Jennifer Kleinhenz, Jacob Usher, James B. O’Keefe, Anne Piantadosi, Jesse J. Waggoner, Ahmed Babiker, David S. Stephens, Evan J. Anderson, Srilatha Edupuganti, Nadine Rouphael, Rafi Ahmed, Jens Wrammert, Mehul S. Suthar
Journal: Cell Host & Microbe (2021)
FP04.04 EGFR Mutations Predict Superior Survival of NSCLC Patients with Oligometastatic Disease Treated with Local Consolidative Therapy
Authors: A. Farooqi, K. Mitchell, E. Ludmir, D. Boyce-Fappiano, A. Vaporciyan, S. Swisher, J. Zhang, X. Le, M. Antonoff, D. Gomez, Y. Elamin, J. Heymach, S. Gandhi
Journal: Journal of Thoracic Oncology (2021)
Abstract S02-03: The impact of the COVID-19 pandemic on Barrett’s esophagus and esophago-gastric cancer
Authors: Richard C. Turkington, Anita Lavery, David Donnelly, Anna T. Gavin, Damian T. McManus, Victoria Cairnduff, Charlene M. McShane, Brian T. Johnston, Lesley A. Anderson, Helen G. Coleman
Journal: Clinical Cancer Research (2021)

Abstract Objective The COVID-19 pandemic has placed an inexorable strain on endoscopy services worldwide, affecting the diagnosis of esophago-gastric (EG) cancer and Barrett’s esophagus (BE). As coronavirus infection rates rose many professional bodies advised that all endoscopy, except emergency and essential procedures, be stopped immediately. We sought to quantify the decline in EG cancer and BE diagnoses following implementation of British Society of Gastroenterology (BSG) guidance related to COVID-19 and the psychosocial effects on BE patients. Methods We examined EG cancer and BE diagnoses in Northern Ireland from March-September 2020 and compared them with the three-year average number of patients during the same time period between 2017-2019 by utilizing Northern Ireland Cancer Registry (NICR) data. The psychosocial impact of COVID-19 was assessed using an online survey, which included validated WHOQOL-BREF and EQ-5D-5L quality of life measures, and was completed by 24 BE patients from April-May 2020. Results During the first six months of the pandemic the proportion of EG cancer and BE diagnoses declined by 26.6% and 59.3%, respectively, compared to expected levels. In April, BE diagnoses fell by 95.5% but by September, whilst EG cancer rates had returned to baseline, BE cases remained suppressed by approximately 20%. We estimate that these declines in diagnosis represent 53 ‘missed’ EG cancer and 236 ‘missed’ BE diagnoses. In the online survey sample, BE patients reported consistently lower quality of life scores than population norms, and highlighted a number of concerns with regard to their health and care. Conclusion The COVID-19 pandemic has resulted in an abrupt decline in EG cancer and BE diagnoses and has profoundly impacted the wellbeing of BE patients. Our study represents the first report of the impact of COVID-19 on the diagnosis of BE. Strategies to mitigate the ongoing effects of the pandemic are urgently required to preserve the ability to rapidly detect and diagnose cancer and pre-malignant conditions. Citation Format: Richard C. Turkington, Anita Lavery, David Donnelly, Anna T. Gavin, Damian T. McManus, Victoria Cairnduff, Charlene M. McShane, Brian T. Johnston, Lesley A. Anderson, Helen G. Coleman. The impact of the COVID-19 pandemic on Barrett’s esophagus and esophago-gastric cancer [abstract]. In: Proceedings of the AACR Virtual Meeting: COVID-19 and Cancer; 2021 Feb 3-5. Philadelphia (PA): AACR; Clin Cancer Res 2021;27(6_Suppl):Abstract nr S02-03.
Phase III, Randomized, Placebo-Controlled Trial of CC-486 (Oral Azacitidine) in Patients With Lower-Risk Myelodysplastic Syndromes
Authors: Guillermo Garcia-Manero, Valeria Santini, Antonio Almeida, Uwe Platzbecker, Anna Jonasova, Lewis R. Silverman, Jose Falantes, Gianluigi Reda, Francesco Buccisano, Pierre Fenaux, Rena Buckstein, Maria Diez Campelo, Stephen Larsen, David Valcarcel, Paresh Vyas, Valentina Giai, Esther Natalie Olíva, Jake Shortt, Dietger Niederwieser, Moshe Mittelman, Luana Fianchi, Ignazia La Torre, Jianhua Zhong, Eric Laille, Daniel Lopes de Menezes, Barry Skikne, C. L. Beach, Aristoteles Giagounidis
Journal: Journal of Clinical Oncology (2021)

Treatment options are limited for patients with lower-risk myelodysplastic syndromes (LR-MDS). This phase III, placebo-controlled trial evaluated CC-486 (oral azacitidine), a hypomethylating agent, in patients with International Prognostic Scoring System LR-MDS and RBC transfusion-dependent anemia and thrombocytopenia.Patients were randomly assigned 1:1 to CC-486 300-mg or placebo for 21 days/28-day cycle. The primary end point was RBC transfusion independence (TI).Two hundred sixteen patients received CC-486 (n = 107) or placebo (n = 109). The median age was 74 years, median platelet count was 25 × 109/L, and absolute neutrophil count was 1.3 × 109/L. In the CC-486 and placebo arms, 31% and 11% of patients, respectively, achieved RBC-TI (P = .0002), with median durations of 11.1 and 5.0 months. Reductions of ≥ 4 RBC units were attained by 42.1% and 30.6% of patients, respectively, with median durations of 10.0 and 2.3 months, and more CC-486 patients had ≥ 1.5 g/dL hemoglobin increases from baseline (23.4% v 4.6%). Platelet hematologic improvement rate was higher with CC-486 (24.3% v 6.5%). Underpowered interim overall survival analysis showed no difference between CC-486 and placebo (median, 17.3 v 16.2 months; P = .96). Low-grade GI events were the most common adverse events in both arms. In the CC-486 and placebo arms, 90% and 73% of patients experienced a grade 3-4 adverse event. Overall death rate was similar between arms, but there was an imbalance in deaths during the first 56 days (CC-486, n = 16; placebo, n = 6), most related to infections; the median pretreatment absolute neutrophil count for the 16 CC-486 patients was 0.57 × 109/L.CC-486 significantly improved RBC-TI rate and induced durable bilineage improvements in patients with LR-MDS and high-risk disease features. More early deaths occurred in the CC-486 arm, most related to infections in patients with significant pretreatment neutropenia. Further evaluation of CC-486 in MDS is needed.
Ushering in safe, effective, secure, and ethical medicine in the digital era
Authors: William J. Gordon, Andrea R. Coravos, Ariel D. Stern
Journal: npj Digital Medicine (2021)

From clinical trials to care delivery, advanced, digitally enabled technologies and analytics offer new approaches to how we think about medicine, health, and biology. The Covid-19 pandemic has accelerated this conversation, and forced a roadmap, once measured in years or decades, to unfold over days, weeks, and months. Yet the scaffolding for this roadmap had already emerged prior to the Covid-19 pandemic. In this perspective, we highlight a special collection of papers on "digital medicine," which emerged from a symposium held in Boston in 2019 and were published in 2020 and 2021. The symposium was hosted by Harvard Business School and the Harvard MIT Center for Regulatory Science, and included a range of speakers and attendees from industry, government, and academics. We describe their ongoing relevance as we contemplate our early 2021 pandemic reality and the near future of digitally empowered health care.
Identification and disruption of a neural mechanism for accumulating prospective metacognitive information prior to decision-making
Authors: Kentaro Miyamoto, Nadescha Trudel, Kevin Kamermans, Michele C. Lim, Alberto Lazari, Lennart Verhagen, Marco K. Wittmann, Matthew F.S. Rushworth
Journal: Neuron (2021)

More than one type of probability must be considered when making decisions. It is as necessary to know one's chance of performing choices correctly as it is to know the chances that desired outcomes will follow choices. We refer to these two choice contingencies as internal and external probability. Neural activity across many frontal and parietal areas reflected internal and external probabilities in a similar manner during decision-making. However, neural recording and manipulation approaches suggest that one area, the anterior lateral prefrontal cortex (alPFC), is highly specialized for making prospective, metacognitive judgments on the basis of internal probability; it is essential for knowing which decisions to tackle, given its assessment of how well they will be performed. Its activity predicted prospective metacognitive judgments, and individual variation in activity predicted individual variation in metacognitive judgments. Its disruption altered metacognitive judgments, leading participants to tackle perceptual decisions they were likely to fail.
P09.39 PD-L1 Testing Patterns and Treatment in Patients With Metastatic Non-Small Cell Lung Cancer in Israel – Analysis of Real-World Data
Authors: L. Apter, S. Sharman Moser, A. Arunachalam, T. Burke, V. Shalev, G. Chodick, N. Siegelmann-Danieli
Journal: Journal of Thoracic Oncology (2021)
P01.06 CX-2029, a Probody Drug Conjugate Targeting CD71 in Patients With Selected Tumor Types: PROCLAIM-CX-2029 Dose Expansion Phase
Authors: M. Johnson, J. Rodon Ahnert, N. Lakhani, R.E. Sanborn, A. El-Khoueiry, N. Hafez, H. Mamdani, V. Boni, H. Castro, A.L. Hannah, A. Spira
Journal: Journal of Thoracic Oncology (2021)
P60.11 TCR Repertoire Predicts Pathological Response in NSCLC Patients Receiving Neoadjuvant Chemoimmunotherapy from NADIM Trial
Authors: M. Casarrubios, E. Nadal, A. Cruz-Bermudez, A. Insa, R. Laza Briviesca, M.R. Garcia Campelo, B. Sierra-Rodero, J. Casal, M. Dómine, B. Massuti, M. Majem Tarruella, D. Rodríguez-Abreu, A. Martinez-Marti, J. De Castro Campeño, M. Cobo Dols, G. López Vivanco, E. Del Barco, R. Bernabé Caro, N. Viñolas, I. Barneto, S. Viteri, M. Jove, F. Franco, M. Provencio
Journal: Journal of Thoracic Oncology (2021)
Comorbidities and diabetic complications in patients with necrobiosis lipoidica
Authors: Kevin J Severson, Meera H Patel, Caitlin M Brumfiel, Ilana Breen, Richard J Butterfield, Steven A Nelson, Aleksander Sekulic, Mark R Pittelkow, Aaron R Mangold
Journal: Journal of the American Academy of Dermatology (2021)
P07.06 Automated Flow Cytometry Test Distinguishes Cancer from Non-Cancer in Sputum with High Sensitivity and Specificity
Authors: V. Rebel, L. Bederka, P. Araujo, J. Sanchez, M. Grayson, M. Lemieux, J. Rebeles, S. Lai, X. Reveles
Journal: Journal of Thoracic Oncology (2021)
Mutated SPOP E3 Ligase Promotes 17βHSD4 Protein Degradation to Drive Androgenesis and Prostate Cancer Progression
Authors: Lei Shi, Yuqian Yan, Yundong He, Binyuan Yan, Yunqian Pan, Jacob J. Orme, Jun Zhang, Wanhai Xu, Jun Pang, Haojie Huang
Journal: Cancer Research (2021)

Abstract Molecular mechanisms underlying intratumoral androgenesis and aberrant androgen receptor (AR) activation in prostate cancer remain poorly understood. Here we demonstrate that ectopic expression of the E3 ubiquitin ligase adaptor speckle-type poxvirus and zinc finger domain protein (SPOP) stabilizes 17βHSD4. SPOP bound a functional substrate-binding consensus (SBC) motif 315RATST319 in 17βHSD4 and promoted nondegradable K27- and K29-linked polyubiquitination of 17βHSD4. The effect of SPOP was antagonized by serum- and glucocorticoid kinase-3 (SGK3)-mediated phosphorylation of serine 318 (S318) in the SBC and S318 phosphorylation-dependent binding of SKP2 E3 ligase and subsequent K48-linked polyubiquitination and proteasomal degradation of 17βHSD4. Prostate cancer–associated SPOP mutations impaired the SPOP-17βHSD4 interaction, caused 17βHSD4 protein destruction in prostate cancer cells in culture and patient specimens, and increased testosterone production and prostate cancer cell growth in vitro and in mouse models. Thus, we have identified SPOP and SKP2 as two essential E3 ubiquitin ligases that exert opposite effects on 17βHSD4 protein degradation and intratumoral androgenesis in prostate cancer cells. We further demonstrate that SPOP mutations or SKP2 overexpression contribute to prostate cancer progression by decreasing 17βHSD4 expression and increasing intratumoral androgen synthesis. Significance: This study reveals a novel mechanism of aberrant AR activation in SPOP-mutated prostate cancer and uncovers putative biomarkers for effective treatment by AR-targeted therapies.
Thyroid hormone plus dual-specificity phosphatase-5 siRNA increases the number of cardiac muscle cells and improves left ventricular contractile function in chronic doxorubicin-injured hearts
Authors: Lin Tan, Nikolay Bogush, Emmen Naqvi, John W Calvert, Robert M Graham, W Robert Taylor, Nawazish Naqvi, Ahsan Husain
Journal: Theranostics (2021)

Doxorubicin is a widely used anticancer drug. However, its major side effect, cardiotoxicity, results from cardiomyocyte loss that causes left ventricle (LV) wall thinning, chronic LV dysfunction and heart failure. Cardiomyocyte number expansion by thyroid hormone (T3) during preadolescence is suppressed by the developmental induction of an ERK1/2-specific dual specificity phosphatase 5 (DUSP5). Here, we sought to determine if a brief course of combined DUSP5 suppression plus T3 therapy replaces cardiomyocytes lost due to preexisting doxorubicin injury and reverses heart failure.
OA05.03 Real-World Global Data on Targeting Epidermal Growth Factor Receptor in Stage III Non-Small Cell Lung Cancer: The Results of the KINDLE Study
Authors: A. Jazieh, H. Onal, D. Tan, R. Soo, K. Prabhash, A. Kumar, R. Huggenberger, S. Robb, B.C. Cho
Journal: Journal of Thoracic Oncology (2021)
Effectiveness of Elastomeric Half-Mask Respirators vs N95 Filtering Facepiece Respirators During Simulated Resuscitation
Authors: Andrew J. Barros, Costi D. Sifri, Taison D. Bell, Joshua C. Eby, Kyle B. Enfield
Journal: JAMA Network Open (2021)

Our results suggest that FFR fit during CPR is poor and that EMHRs provide superior fit, confirming previous research. 5 We chose to evaluate fit during CPR because it is highly aerosolizing, physically strenuous, and has been associated with occupational transmission.Strengths of our study include our real-world design and prospective data collection.Limitations include the lack of blinding or randomization and the use of participant-reported detection.The data suggest that the EMHR is more effective at preventing aerosol inhalation during strenuous clinical work and should be considered for preventing COVID-19 transmission.
Abstract 14161: Genetic Deletion of P66ShcProtects Against Obesity-Induced Mitochondrial Dysfunction, Oxidative Stress and Vascular Inflammation
Authors: Francesco Paneni, Giuliana Capretti, Sarah Costantino, Sergio Chiandotto, Enrico Di Stasio, Alexander Akhmedov, Giovanna Petrucci, Bianca Rocca, Thomas Luscher, Massimo Volpe, Francesco Cosentino
Journal: Circulation (2012)

Introduction: Leptin deficiency in mice (LepOb/Ob) triggers high caloric intake leading to obesity/insulin resistance and activates several reactive oxygen species (ROS) generating pathways. The mi...
P09.14 Predictive Analytics in Real-World Data from Peru: The New Models for Personalized Oncology
Authors: L. Pino, I. Triana, J. Mejia, M. Camelo, M. Galvez-Nino, R. Ruiz, K. Roque, J. Moreno, M. Olivera, N. Valdiviezo, O. Coanqui, L. Mas
Journal: Journal of Thoracic Oncology (2021)
Single-cell transcriptome analysis of the heterogeneous effects of differential expression of tumor PD-L1 on responding TCR-T cells
Authors: Renpeng Ding, Shang Liu, Shanshan Wang, Huanyi Chen, Fei Wang, Qumiao Xu, Linnan Zhu, Xuan Dong, Ying Gu, Xiuqing Zhang, Cheng-Chi Chao, Qianqian Gao
Journal: Theranostics (2021)

TCR-T cell therapy plays a critical role in the treatment of malignant cancers. However, it is unclear how TCR-T cells are affected by PD-L1 molecule in the tumor environment. We performed an in-depth evaluation on how differential expressions of tumor PD-L1 can affect the functionality of T cells.
Trends in obesity and adiposity measures by race or ethnicity among adults in the United States 2011-18: population based study
Authors: Buyun Liu, Yang Du, Yuxiao Wu, Linda G Snetselaar, Robert B Wallace, Wei Bao
Journal: BMJ (2021)

Abstract Objective To examine the trends in obesity and adiposity measures, including body mass index, waist circumference, body fat percentage, and lean mass, by race or ethnicity among adults in the United States from 2011 to 2018. Design Population based study. Setting National Health and Nutrition Examination Survey (NHANES), 2011-18. Participants A nationally representative sample of US adults aged 20 years or older. Main outcome measures Weight, height, and waist circumference among adults aged 20 years or older were measured by trained technicians using standardized protocols. Obesity was defined as body mass index of 30 or higher for non-Asians and 27.5 or higher for Asians. Abdominal obesity was defined as a waist circumference of 102 cm or larger for men and 88 cm or larger for women. Body fat percentage and lean mass were measured among adults aged 20-59 years by using dual energy x ray absorptiometry. Results This study included 21 399 adults from NHANES 2011-18. Body mass index was measured for 21 093 adults, waist circumference for 20 080 adults, and body fat percentage for 10 864 adults. For the overall population, age adjusted prevalence of general obesity increased from 35.4% (95% confidence interval 32.5% to 38.3%) in 2011-12 to 43.4% (39.8% to 47.0%) in 2017-18 (P for trend&lt;0.001), and age adjusted prevalence of abdominal obesity increased from 54.5% (51.2% to 57.8%) in 2011-12 to 59.1% (55.6% to 62.7%) in 2017-18 (P for trend=0.02). Age adjusted mean body mass index increased from 28.7 (28.2 to 29.1) in 2011-12 to 29.8 (29.2 to 30.4) in 2017-18 (P for trend=0.001), and age adjusted mean waist circumference increased from 98.4 cm (97.4 to 99.5 cm) in 2011-12 to 100.5 cm (98.9 to 102.1 cm) in 2017-18 (P for trend=0.01). Significant increases were observed in body mass index and waist circumference among the Hispanic, non-Hispanic white, and non-Hispanic Asian groups (all P for trend&lt;0.05), but not for the non-Hispanic black group. For body fat percentage, a significant increase was observed among non-Hispanic Asians (30.6%, 29.8% to 31.4% in 2011-12; 32.7%, 32.0% to 33.4% in 2017-18; P for trend=0.001), but not among other racial or ethnic groups. The age adjusted mean lean mass decreased in the non-Hispanic black group and increased in the non-Hispanic Asian group, but no statistically significant changes were found in other racial or ethnic groups. Conclusions Among US adults, an increasing trend was found in obesity and adiposity measures from 2011 to 2018, although disparities exist among racial or ethnic groups.